Evidence map›Paper›PMID 22685291›Full record

ArticleThe Journal of biological chemistry2012

Gemfibrozil, a lipid-lowering drug, induces suppressor of cytokine signaling 3 in glial cells: implications for neurodegenerative disorders.

Arunava Ghosh, Kalipada Pahan

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Activation of PPARα Exhibits Therapeutic Efficacy in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  13. Article
  14. Article
  15. Article
  16. Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARα-Dependent Astrocytic GDNF Pathway.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Arunava GhoshDepartment of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA.
Kalipada Pahan
Rush University Medical Center · US

Funding

Cinnamon, CNTF and EAER01AT006681 · NCCIH · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2011 to 2015
$1.8M
NEMO-binding domain peptide in a monkey model of PDR21NS064564 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2010 to 2011
$410k
Castration of male mice: An unexpected way to model PD pathologiesR21NS071479 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI PAHAN, KALIPADA · 2010 to 2011
$409k
NCCIH NIH HHS AT6681NCCIH NIH HHS R01 AT006681NINDS NIH HHS NS64564NINDS NIH HHS NS71479NINDS NIH HHS R21 NS064564NINDS NIH HHS R21 NS071479
6 · The paper itself

Abstract

Glial inflammation is an important feature of several neurodegenerative disorders. Suppressor of cytokine signaling (SOCS) proteins play a crucial role in inhibiting cytokine signaling and inflammatory gene expression in various cell types, including glial cells. However, mechanisms by which SOCS genes could be up-regulated are poorly understood. This study underlines the importance of gemfibrozil, a Food and Drug Administration-approved lipid-lowering drug, in up-regulating the expression of SOCS3 in glial cells. Gemfibrozil increased the expression of Socs3 mRNA and protein in mouse astroglia and microglia in both a time- and dose-dependent manner. Interestingly, gemfibrozil induced the activation of type IA phosphatidylinositol (PI) 3-kinase and AKT. Accordingly, inhibition of PI 3-kinase and AKT by chemical inhibitors abrogated gemfibrozil-mediated up-regulation of SOCS3. Furthermore, we demonstrated that gemfibrozil induced the activation of Krüppel-like factor 4 (KLF4) via the PI 3-kinase-AKT pathway and that siRNA knockdown of KLF4 abrogated gemfibrozil-mediated up-regulation of SOCS3. Gemfibrozil also induced the recruitment of KLF4 to the distal, but not proximal, KLF4-binding site of the Socs3 promoter. This study delineates a novel property of gemfibrozil in up-regulating SOCS3 in glial cells via PI 3-kinase-AKT-mediated activation of KLF4 and suggests that gemfibrozil may find therapeutic application in neuroinflammatory and neurodegenerative disorders.

Indexed as

Base SequenceCells, CulturedDNA PrimersGemfibrozilHumansHypolipidemic AgentsKruppel-Like Factor 4Neurodegenerative DiseasesRNA, MessengerSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling ProteinsDNA PrimersGemfibrozilHypolipidemic AgentsKLF4 protein, humanKlf4 protein, mouseKruppel-Like Factor 4RNA, MessengerSocs3 protein, mouseSuppressor of Cytokine Signaling 3 ProteinSuppressor of Cytokine Signaling Proteins

Identifiers

PMID22685291
PMCPMC3411061
OpenAlexW2026094227

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.